CompletedNCT03227224
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Medication studyAges 18–70Multiple countriesDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- Anaheim and 100 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 16, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 287
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, France, Bulgaria, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT03227224
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Get this study by email
Recruitment & locations
CompletedAnaheim, United States · Chino, United States · Lemon Grove, United States
81 more locations
- Panorama City, United States
- San Diego, United States
- San Rafael, United States
- Torrance, United States
- Wildomar, United States
- Gainesville, United States
- Hallandale, United States
- Jacksonville, United States
- Lauderhill, United States
- Miami, United States
- Miami Springs, United States
- North Miami, United States
- Orlando, United States
- Atlanta, United States
- Chicago, United States
- Joliet, United States
- New York, United States
- Staten Island, United States
- Winston-Salem, United States
- Canton, United States
- Dayton, United States
- Media, United States
- The Woodlands, United States
- Everett, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Lovech, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Tzarev Brod, Bulgaria
- Varna, Bulgaria
- Veliko Tarnovo, Bulgaria
- Helsinki, Finland
- Kuopio, Finland
- Oulu, Finland
- Rauma, Finland
- Clermont-Ferrand, France
- Douai, France
- Nîmes, France
- Paris, France
- Rennes, France
- Bad Homburg, Germany
- Chemnitz, Germany
- Dresden, Germany
- Schwerin, Germany
- Bunkyō City, Japan
- Fukuoka, Japan
- Ichikawa-shi, Japan
- Kanzaki-gun, Japan
- Kashihara-shi, Japan
- Meguro-ku, Japan
- Nakano, Japan
- Omuta-shi, Japan
- Sagamihara-shi, Japan
- Setagaya-ku, Japan
- Shibuya-ku, Japan
- Shinagawa-ku, Japan
- Shinjuku-ku, Japan
- Toshima-ku, Japan
- Arkhangelsk, Russia
- Moscow, Russia
- Omsk, Russia
- Rostov-on-Don, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Saratov Region, Russia
- Tomsk, Russia
- Yekaterinburg, Russia
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Oleksandrivka, Ukraine
- Poltava, Ukraine
- Ternopil, Ukraine
- Vinnytsia, Ukraine
- Russia
Questions about this study
What did participation involve?
The protocol called for participants to take study medication.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Placebo and JNJ-42847922.
Who was this study for?
Listed age limits: 18 years to 70 years.
